BJRI vs HEPS

BJRI's Piotroski F-Score of 4/9 indicates weak financial health, signaling distress in operational efficiency and capital structure. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given a dangerously high Debt/Equity ratio of 1.41 and extremely low liquidity ratios (Current Ratio: 0.36, Quick Ratio: 0.21). While the company shows strong earnings surprise history and recent EPS growth of 130.8% YoY, these gains are likely driven by one-time or cyclical factors, as evidenced by negative operating margins (-0.13%) and inconsistent profitability. The stock trades at a premium to its intrinsic value and Graham number, suggesting overvaluation despite modest revenue growth. Analysts recommend 'buy' but with limited conviction, as the technical trend is bearish and insider sentiment is neutral.

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.